2BBBullish & Bearish
Myriad Genetics, Inc. (MYGN) trades on NASDAQ. It operates in the Health Care sector, Diagnostics & Research industry. Its current 2BB score is 49 out of 100.
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease.
Myriad Genetics, Inc.’s current 2BB score is 49 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 47 | Moderate |
| Momentum | 48 | Stable |
| Financial strength | 26 | Weak |
| Quality | 100 | Very Strong |
| Risk | 46 | Moderate |
| CEO | Paul J. Diaz | Paul J. Diaz |
| Headquarters | Salt Lake City, Utah, United States |
| Founded | 1991 |
| Employees | 2.7K |
| 52-week range | $2.74 – $8.59 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-22 | — | -0.1985 | — | $199.76M |
| 2026-11-02 | — | -0.217 | — | $195.15M |
| 2026-07-30 | — | -0.059 | — | $210.15M |
| 2026-05-05 | -0.09 | -0.0698 | $200.40M | $206.53M |